114 related articles for article (PubMed ID: 2121912)
1. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects.
Tempero MA; Sivinski C; Steplewski Z; Harvey E; Klassen L; Kay HD
J Clin Oncol; 1990 Dec; 8(12):2019-26. PubMed ID: 2121912
[TBL] [Abstract][Full Text] [Related]
2. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
Weiner LM; Steplewski Z; Koprowski H; Litwin S; Comis RL
Cancer Res; 1988 Feb; 48(4):1042-6. PubMed ID: 3123051
[TBL] [Abstract][Full Text] [Related]
3. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
4. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma.
Weiner LM; Steplewski Z; Koprowski H; Sears HF; Litwin S; Comis RL
Hybridoma; 1986 Jul; 5 Suppl 1():S65-77. PubMed ID: 3091476
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma.
Tempero MA; Haga Y; Sivinski C; Steplewski Z; Kay HD; Pour P
Int J Pancreatol; 1991; 9():125-34. PubMed ID: 1744438
[TBL] [Abstract][Full Text] [Related]
6. Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon gamma.
Blottiere HM; Douillard JY; Koprowski H; Steplewski Z
Cancer Immunol Immunother; 1990; 32(1):29-37. PubMed ID: 2126982
[TBL] [Abstract][Full Text] [Related]
7. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
Giantonio BJ; Alpaugh RK; Schultz J; McAleer C; Newton DW; Shannon B; Guedez Y; Kotb M; Vitek L; Persson R; Gunnarsson PO; Kalland T; Dohlsten M; Persson B; Weiner LM
J Clin Oncol; 1997 May; 15(5):1994-2007. PubMed ID: 9164211
[TBL] [Abstract][Full Text] [Related]
8. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer.
Tempero MA; Pour PM; Uchida E; Herlyn D; Steplewski Z
Hybridoma; 1986 Jul; 5 Suppl 1():S133-8. PubMed ID: 3744378
[TBL] [Abstract][Full Text] [Related]
10. Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy.
Blottière HM; Steplewski Z; Herlyn D; Douillard JY
Hum Antibodies Hybridomas; 1991 Jan; 2(1):16-25. PubMed ID: 1908336
[TBL] [Abstract][Full Text] [Related]
11. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
[TBL] [Abstract][Full Text] [Related]
12. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
[TBL] [Abstract][Full Text] [Related]
13. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data.
Saleh MN; LoBuglio AF; Wheeler RH; Rogers KJ; Haynes A; Lee JY; Khazaeli MB
Cancer Immunol Immunother; 1990; 32(3):185-90. PubMed ID: 2126988
[TBL] [Abstract][Full Text] [Related]
15. Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes.
Hanibuchi M; Yano S; Nishioka Y; Yanagawa H; Sone S
Jpn J Cancer Res; 1996 May; 87(5):497-504. PubMed ID: 8641987
[TBL] [Abstract][Full Text] [Related]
16. Phase I studies of recombinant interferon-gamma.
Laszlo J; Goldstein D; Gockerman J; Hood L; Huang AT; Triozzi P; Sedwick WD; Koren H; Ellinwood EH; Tso CY
J Biol Response Mod; 1990 Apr; 9(2):185-93. PubMed ID: 2160521
[TBL] [Abstract][Full Text] [Related]
17. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.
Kirkwood JM; Ernstoff MS; Trautman T; Hebert G; Nishida Y; Davis CA; Balzer J; Reich S; Schindler J; Rudnick SA
J Clin Oncol; 1990 Jun; 8(6):1070-82. PubMed ID: 2112184
[TBL] [Abstract][Full Text] [Related]
18. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
19. m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer.
Pullyblank AM; Guillou PJ; Monson JR
Br J Cancer; 1994 Oct; 70(4):753-8. PubMed ID: 7917934
[TBL] [Abstract][Full Text] [Related]
20. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
